drugset / Trial / NCT07298395

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395 ↗

Phase 2 Recruiting 60 enrolled Enveda Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16

Timeline

Start
2025-12-22
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ENV-294 Unknown — Oral

Indications